AB122 is a monoclonal antibody  (mAb) that potently and selectively blocks a protein called PD-1. This immune checkpoint is expressed by tumor-infiltrating T cells that recognize tumor antigens but have become exhausted by chronic exposure to those antigens in the tumor’s tolerogenic environment.

By producing proteins (PD-L1 and PD-L2) that bind to PD-1, cancer cells and even immune cells in the tumor micro-environment can interfere with the ability of T cells to mount an effective anti-tumor response. Like other agents in this class that have already received regulatory approval, AB122 potently and selectively blocks this interaction between PD-1 and its ligands, which we expect will result in a powerful anti-tumor effect. AB122 is currently in a Phase 1 trial in cancer patients and is also being evaluated in our Phase 1/1b program in combination with AB928.

AB122 Clinical Trials Currently Enrolling

Trial Summary

A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors.

Trial Identifier

Publications and Abstracts

November 7-November 11, 2018

Development of a robust, simplified method to measure receptor occupancy in peripheral blood from patients treated with a novel anti-PD1 agent, AB122. Ashok D, Piovesan D, Zhao X, Singh H, Walters MJ, Young S, Seitz L. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P15; abstract No. 10495.

View Poster

November 7-November 11, 2018

Preliminary Results from an Ongoing Phase 1 Study of AB122, an Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibody, in Patients with Advanced Solid Tumors. De Souza, Lee CK, Sjoquist K, Pan S, Idan A, Rieger A, Berry W, Jin L, Seitz L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee SJ, Park A, DiRenzo D, Karakunnel J. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P673; abstract No. 10638.

View Poster

April 14-18, 2018

Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody. Tan JBL, Chen C, Chen K, Li G, Li J, Liu J, Singh H, Wang G, Yang B, Zhang K, Zhao X, Zheng Y. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4561.

View Poster